skip to main content

Narrow therapeutic index brand continuity — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

EasyDispensing and SupplyNarrow therapeutic index brand continuityGPhC CRA

A patient taking tacrolimus after a kidney transplant presents a repeat prescription with no brand specified. The pharmacy has a different brand from the patient's usual supply. What is the most appropriate alternative?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Confirm the brand with the prescriber or transplant team before changing

Tacrolimus is a narrow therapeutic index medicine where brand changes can affect exposure. Brand continuity is generally recommended unless switching is clinically supervised. The pharmacist should clarify before supply to avoid rejection or toxicity risk.

Reference: BNF; MHRA